China Adalimumab Market Investigation Report 2021: Sales 2016-2020, Key Manufacturers 2016-2020, Price 2020-2021, Outlook 2021-2025


DUBLIN, January 07, 2022– (COMMERCIAL THREAD)–The “Chinese Adalimumab Market Investigation Report, 2021-2025” the report was added to offer.

Sales of Adalimumab increased significantly in 2020, reaching around CNY 101.11 million (2019 revenue is CNY 14.15 million), and the CAGR is around 38% from 2016 to 2020. .

Thus, the analyst analyzes that with the emergence of generic drugs, the choice of drugs is increasing. Therefore, the price of drugs will go down. Coupled with the tight control of adjuvant drugs and improved medical insurance policies, adalimumab is expected to be more popular in China in 2021-2025, and sales will also increase as a result.

In 2010, adalimumab entered the Chinese market. Its original drug is produced by AbbVie Inc. under the brand name HUMIRA.

Sales of HUMIRA rank first among all pharmaceuticals because it is used for a large number of disease treatments (such as treatment of arthritis, Crohn’s disease, ulcerative colitis, etc. .). However, unlike the EU and North America market, adalimumab is not popular in the Chinese market.

From 2016 to 2019, sales of Adalimumab gradually declined for three reasons. The first is that it is not included in medical insurance, while its price is around CNY7,600 per injection, so a patient spends around CNY 10,000-20,000 on the drug.

Second, adalimumab has significantly fewer indications approved in China than in the EU and NA countries (including indications for rheumatoid arthritis approved in 2010, indications for ankylosing spondylitis approved in 2013, and indications for psoriasis approved in 2017). Finally, adjuvant drugs have long dominated the Chinese drug sales market.

In contrast, after the sales decline from 2016 to 2019, sales of Adalimumab in the Chinese market increased by approximately 7 times in 2020 compared to the previous year. The substantial increase is mainly due to the improvement of medical insurance policies and the rectification of the abuse of adjuvant drugs. In addition, more and more generic drugs are appearing on the market since the HUMIRA patent is about to expire.

Although Abbvie Inc. successfully pushed back the threat of US biosimilars to 2023, it lost its patent protection in Europe on October 16, 2018. In China, 28 companies have filed generic drug applications for Adalimumab biosimilars in 2019. In 2020, three companies launched generic drugs, namely Zhejiang Hisun Pharmaceutical Co., Ltd., Bio-Thera Solutions, Ltd. and Innovent Biologics (Suzhou) Co., Ltd.

Topics covered:

  • The impact of COVID-19 on the Chinese adalimumab market

  • China Adalimumab Sales Value and Volume 2016-2020

  • Competitive landscape of the Chinese adalimumab market

  • Adalimumab price in China

  • Adalimumab Price in China by Regions and Manufacturers

  • Analysis of factors affecting the development of the Chinese Adalimumab Market

  • China Adalimumab Market Outlook from 2021 to 2025

Main topics covered:

1 Relevant concepts of adalimumab

1.1 Indications for adalimumab

1.2 Development of Adalimumab in China

1.3 Government approval of adalimumab in China

1.4 The impact of COVID-19 on sales of adalimumab in China

2 Sales of Adalimumab in China, 2016-2020

2.1 Sales value of adalimumab

2.1.1 Overall value of sales

2.1.2 Sales value by region

2.2 Adalimumab sales volume

2.2.1 Global sales volume

2.2.2 Sales Volume by Region

2.3 China Adalimumab Sales by Dosage Form, 2016-2020

2.3.1 Injection

2.3.2 Analysis of other dosage forms

3 China Adalimumab Major Manufacturers Analysis, 2016-2020

3.1 Major Manufacturers of Adalimumab Market Share Analysis

3.1.1 Market Share by Sales Value Survey

3.1.2 Market Share by Sales Volume Survey

3.2 AbbVie Ltd.

3.2.1 Company profile

3.2.2 Sales of HUMIRA (AbbVie’s Adalimumab) in China

3.3 Zhejiang Hisun Pharmaceutical Co., Ltd.

3.3.1 Company profile

3.3.2 Sales of Anjianning (Hisun’s Adalimumab) in China

3.4 Bio-Thera Solutions, Ltd.

3.4.1 Company profile

3.4.2 Sales of OLETLI (Adalimumab by Bio-Thera) in China

3.5 Innovent Biologics (Suzhou) Co., Ltd.

3.5.1 Company Profile

3.5.2 Sales of SULINNO (Adalimumab from Innovent) in China

4 Adalimumab Price for Different Manufacturers in China, 2020-2021

4.1 AbbVie Ltd. (HUMIRA)

4.2 Zhejiang Hisun Pharmaceutical Co., Ltd. (Anjianning)

4.3 Bio-Thera Solutions, Ltd. (OLETLI)

4.4 Innovent Biologics (Suzhou) Co., Ltd. (SULINNO)

5 China Adalimumab Drug Market Outlook, 2021-2025

5.1 Factors influencing the development of the Chinese adalimumab market

5.1.1 The impact of COVID-19 on the Chinese adalimumab market

5.1.2 Market Drivers and Opportunities

5.1.3 Market threats and challenges

5.2 Market Size Forecast

5.3 Market Trend Forecast

For more information on this report, visit

See the source version on

Laura Wood, Senior Press Director
[email protected]
For EST office hours, call 1-917-300-0470
For USA / CAN call toll free 1-800-526-8630
For GMT office hours, call + 353-1-416-8900


Comments are closed.